Replies to post #300114 on Amarin Corp Plc (AMRN)

[raistthemage]

I'm not better than that I consider JT to be a personal enemy of mine who has cost me what should have been millions of dollars. He could have learned to be a better speaker (perhaps never a good one but he could have learned to be passable) but he never has...

He never has because he never cared about doing anything with this company instead of looting it.

But the most unforgivable stupid decision of all was filing in the 9th circuit, he needed to maximize the chance for a conservative/republican judge who would respect Amarin's intellectual property but they did the exact opposite.

Now he wants to GIA in Europe instead of making an immediate Authorized Generic deal, its clear he is going to continue to make bad decisions. He has to go lets not defend him...

The immense value of Vascepa can still be mostly salvaged (I would say at least 80% of what its value should have been) but we need to make an Authorized Generic deal ASAP to do it and the stammering moron thief is in the way.

[DD222]

Irish,

I think the strategy is spelled out for everyone during every call. We hear the same information consistently. GIA, marketing in Q3, possibly limited supply for generics , hard to manufacture, so on and so fourth. The only thing that’s changed is perception of the reversal. We went from feeling strongly about a reversal to a long shot for reversal. If the Hail Mary is caught for TD then I will have been wrong. IMO Amarin will launch as generic and take as much market share as they can until it starts to level of due to competition. This unfortunately means a very long road for investors. I would be surprised if there as was a BO. Our CEO is telling us exactly what to expect.

[Lrich]

His speaking skills are literally part of his job and have a direct effect the stock price (and therefore, our net worth), therefore that is fair game.

[Will Lar]

Irishman - not over commenting management's strategy without knowing the reason behind it, is reasonable. I admire you saying this.

But you know (no pun intended), the nature of the company has changed in the course of 2019, from a development focused company to a sales-marketing focused one. Before 2019 or September 2018, the company's focus was on trials, Marine, Anchor and then ReducedIt. The sales expectation was moderate, and all eyes were on trials. As the CEO, JT's responsibility was to complete the trial while managing as much sales as he could, i.e., more operation focused. Granted that ReducedIt was the first global CV outcome trial, its thesis including trial design was built upon MANY previous studies done by OTHER people. Amarin didn't have a meaningful lab or R&D in its entire existence. It was only focused on trials, first neuro, then cardio. I don't know about other shareholders, but I invested because I trusted the thousands of O3 and EPA studies published overall the world including Mori, Kura, etc., specifically JELIS. I have faith in the collective scientific observation, NOT Amarin per se.

After Sept 2018, the development era is largely over. The company needs to pickup sales as it does not have a pipeline or R&D! Sales is solely relied on the management. I don't think they're doing that well. Yes COVID can be one of the reasons, but JT just doesn't strike me as a jazzy sales and marketing people, YOU KNOW. So shareholders should be worried. If you're not worried, then you don't really know what a fight this company is facing and how unprepared this management team is.